Literature DB >> 19484521

[Analysis of QRST integral and QT dispersion by body surface potential mapping in patients with malignant ventricular arrhythmias].

C Stellbrink1, E Stegemann, R Killmann, K Mischke, H Schütt, P Hanrath.   

Abstract

In a retrospective analysis in 74 patients with coronary artery disease or no obvious heart disease, the value of "body surface potential mapping" for the identification of repolarization abnormalities was investigated compared to the standard 12-lead ECG. In patients with idiopathic ventricular fibrillation the number of extrema in the QRST integral map was significantly higher than in the control group (3.15+/-0.99 vs. 2.17+/-0.51, p<0.001) and the QT dispersion was also higher (0.10+/-0.03 vs. 0.07+/-0.01, p<0.001), whereas there was no difference between either group in the 12-lead ECG QT dispersion. In patients with coronary artery disease the number of extrema in the QRST integral map and QT dispersion were also higher compared to the control group, but there were no significant differences between patients with or without aborted sudden cardiac death.In conclusion, BSPM identifies repolarization abnormalities not detected by 12-lead ECG, thereby identifying a potential reason for cardiac arrest in patients without overt heart disease. The usefulness of this technique for risk stratification in patients with coronary artery disease remains to be elucidated.

Entities:  

Year:  1997        PMID: 19484521     DOI: 10.1007/BF03042497

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  29 in total

Review 1.  Clinical applications of body surface potential mapping.

Authors:  L S Green; J A Abildskov
Journal:  Clin Cardiol       Date:  1995-05       Impact factor: 2.882

2.  QT interval prolongation as predictor of sudden death in patients with myocardial infarction.

Authors:  P J Schwartz; S Wolf
Journal:  Circulation       Date:  1978-06       Impact factor: 29.690

3.  Electrocardiographic body surface mapping in patients with ventricular tachycardia. Assessment of utility in the identification of effective pharmacological therapy.

Authors:  L B Mitchell; C L Hubley-Kozey; E R Smith; D G Wyse; H J Duff; A M Gillis; B M Horacek
Journal:  Circulation       Date:  1992-08       Impact factor: 29.690

4.  Value of body surface mapping in localizing the site of origin of ventricular tachycardia in patients with previous myocardial infarction.

Authors:  A Sippensgroenewegen; H Spekhorst; N M van Hemel; J H Kingma; R N Hauer; J M de Bakker; C A Grimbergen; M J Janse; A J Dunning
Journal:  J Am Coll Cardiol       Date:  1994-12       Impact factor: 24.094

5.  Prolonged QT interval at onset of acute myocardial infarction in predicting early phase ventricular tachycardia.

Authors:  G J Taylor; R S Crampton; R S Gibson; P T Stebbins; M T Waldman; G A Beller
Journal:  Am Heart J       Date:  1981-07       Impact factor: 4.749

6.  Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report.

Authors:  P Brugada; J Brugada
Journal:  J Am Coll Cardiol       Date:  1992-11-15       Impact factor: 24.094

7.  Spatial features in body-surface potential maps can identify patients with a history of sustained ventricular tachycardia.

Authors:  C L Hubley-Kozey; L B Mitchell; M J Gardner; J W Warren; C J Penney; E R Smith; B M Horácek
Journal:  Circulation       Date:  1995-10-01       Impact factor: 29.690

8.  Dispersion of ventricular repolarization and arrhythmic cardiac death in coronary artery disease.

Authors:  W Zareba; A J Moss; S le Cessie
Journal:  Am J Cardiol       Date:  1994-09-15       Impact factor: 2.778

9.  Effects of age, sex, and race on ECG interval measurements.

Authors:  P W Macfarlane; S C McLaughlin; B Devine; T F Yang
Journal:  J Electrocardiol       Date:  1994       Impact factor: 1.438

10.  QT dispersion and sudden unexpected death in chronic heart failure.

Authors:  C S Barr; A Naas; M Freeman; C C Lang; A D Struthers
Journal:  Lancet       Date:  1994-02-05       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.